JNJ241115P235000
- 0.00
- 0.000.00%
Johnson & Johnson Newsroom
Johnson & Johnson Initiated at Outperform by Wolfe Research
Johnson & Johnson Analyst Ratings
Wolfe Research Upgrades Johnson & Johnson(JNJ.US) to Buy Rating, Raises Target Price to $190
Johnson & Johnson Analyst Ratings
Guggenheim Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Cuts Target Price to $162
Guggenheim Adjusts Johnson & Johnson's Price Target to $162 From $156, Keeps Neutral Rating
Daiwa Securities Adjusts Price Target on Johnson & Johnson to $170 From $150, Maintains Neutral Rating
A Quick Look at Today's Ratings for Johnson & Johnson(JNJ.US), With a Forecast Between $166 to $185
Goldman Sachs Lowers Price Target on Johnson & Johnson to $159 From $162
Johnson & Johnson Price Target Raised to $166.00/Share From $163.00 by Wells Fargo
A Quick Look at Today's Ratings for Johnson & Johnson(JNJ.US), With a Forecast Between $166 to $215
Johnson & Johnson Is Maintained at Outperform by RBC Capital
Johnson & Johnson Analyst Ratings
Johnson & Johnson (JNJ) Receives a Buy From Cantor Fitzgerald
Bernstein Adjusts Price Target on Johnson & Johnson to $177 From $171, Maintains Market Perform Rating
Hold Rating for Johnson & Johnson Amid 2024 Growth Deceleration and 2025 Optimism
Stifel Raises Johnson & Johnson's Price Target to $170 From $160
DBS Maintains Johnson & Johnson(JNJ.US) With Hold Rating
Johnson & Johnson: Navigating Pharmaceutical Opportunities and Patent Challenges – A Hold Rating Analysis
Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $169